{"anticipatedPostingDate":"2028-09","calculatePct":false,"denomUnitsSelected":"Participants","description":"TEAEs were defined as events that were new or worsened on or after receiving the first dose of study treatment and up through 30 days after the last dose of study treatment. Treatment emergent laboratory abnormalities include: hematology (hemoglobin decreased, hemoglobin increased, leukocytes decreased, neutrophils decreased, platelets decreased); chemistry (alanine aminotransferase increased, alkaline phosphatase increased, aspartate aminotransferase increased, creatinine increased, potassium decreased, potassium increased, sodium decreased, sodium increased, total bilirubin increased).","reportingStatus":"NOT_POSTED","timeFrame":"From first dose of study treatment (Day 1) up to 30 days after the last dose of study treatment (maximum up to 66.7 months)","title":"Number of Participants With Treatment Emergent Laboratory Abnormalities","type":"SECONDARY"}